Frontiers in Microbiology (May 2023)
Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice
- Ruoyao Qi,
- Ruoyao Qi,
- Jiali Cao,
- Yangtao Wu,
- Yangtao Wu,
- Xing Lei,
- Xing Lei,
- Jinhang He,
- Jinhang He,
- Liang Zhang,
- Liang Zhang,
- Rao Fu,
- Rao Fu,
- Feng Chen,
- Feng Chen,
- Yingbin Wang,
- Yingbin Wang,
- Tianying Zhang,
- Tianying Zhang,
- Ningshao Xia,
- Ningshao Xia,
- Quan Yuan
Affiliations
- Ruoyao Qi
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China
- Ruoyao Qi
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian, China
- Jiali Cao
- Department of Clinical Laboratory, Women and Children’s Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Yangtao Wu
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China
- Yangtao Wu
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian, China
- Xing Lei
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China
- Xing Lei
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian, China
- Jinhang He
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China
- Jinhang He
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian, China
- Liang Zhang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China
- Liang Zhang
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian, China
- Rao Fu
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China
- Rao Fu
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian, China
- Feng Chen
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China
- Feng Chen
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian, China
- Yingbin Wang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China
- Yingbin Wang
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian, China
- Tianying Zhang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China
- Tianying Zhang
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian, China
- Ningshao Xia
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China
- Ningshao Xia
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian, China
- Quan Yuan
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China
- DOI
- https://doi.org/10.3389/fmicb.2023.1173061
- Journal volume & issue
-
Vol. 14
Abstract
Chronic infection with the hepatitis B virus (HBV) is a leading causes of liver cirrhosis and hepatocellular carcinoma. However, managing HBV treatments is challenging due to the lack of effective monotherapy. Here, we present two combination approaches, both of which aim to target and enhance the clearance of HBsAg and HBV-DNA. The first approach involves the use of antibodies to continuously suppress HBsAg, followed by the administration of a therapeutic vaccine in a sequential manner. This approach results in better therapeutic outcomes compared to the use of these treatments individually. The second approach involves combining antibodies with ETV, which effectively overcomes the limitations of ETV in suppressing HBsAg. Thus, the combination of therapeutic antibodies, therapeutic vaccines, and other existing drugs is a promising strategy for the development of novel strategies to treat hepatitis B.
Keywords
